Summary Further results are presented from the Swedish two-county breast cancer screening trial. The reduction in the rate of advanced cancers and of breast cancer mortality in the group allocated to screening when compared to the control group has accelerated with a further year of follow-up. Mortality due to other causes and the rate of other cancers remains similar in the two groups. Attention has been focused on the rate at which cancers start re-emerging among women with negative mammograms. Among women over 50 years of age at entry to the study, relatively few interval cancers are seen in the first two years after a screening test; in the third year the rate rises to nearly 50% of the comparable rate in the control group. Among women aged 40-49 years at entry, by contrast, the rate of interval cancers even in the first post screening year is nearly 40% of that in the controls and in the second year nearly 70%. In older women in the group allocated to screening, much of the breast cancer mortality comes from the refusers and little from the interval cancers; in younger women the picture is reversed. The implications for screening policy, including the interscreening interval are discussed.
The potential of mass screening to reduce mortality from breast cancer has been clearly demonstrated by the HIP study from New York (Shapiro et al., 1982) , the Swedish two-county study and by the studies from the Netherlands (Colette et al., 1984; Verbeek et al., 1984) . The qeustions that now arise concern the implementation of breast cancer screening, in particular who should be screened and how often. The two-county Swedish study was designed with a longer inter-screening interval than the HIP or Dutch studies and thus is an invaluable source of information concerning these questions. This longer interval gives the opportunity to analyze the incidence of interval cancers in the second and third years after screening. It is of special interest to examine how the incidence of these interval cancers increases as time elapses since the last screening test Walter et al., 1983) , especially because interval cancers, i.e. breast carcinomas diagnosed between screening examinations, appear to have a similar prognosis to cancers diagnosed-in an unscreened population (Shapiro et al., 1982; Holmberg et al., 1986) . As the interval cancer incidence approaches to that of the control population, the effect of screening disappears. Thus, a necessary condition for effective screening is that the total incidence of interval cancers is kept relatively low. Our most recent results have given us the opportunity to examine the incidence of interval cancers after the first and second rounds, in each age group. Our purpose is to study the effect of interval length on the efficacy of screening.
Subjects and methods
The design of the study has been described in detail previously (Tab'ar et al., 1985) . In brief, a total of 162,981 women aged 40 or more were randomly assigned either to be offered or not offered regular single-view mammography at specialised screening centres. The randomisation was performed on a population-block basis consisting of small administrative units (parishes, municipalities Screening of the control population started after the completion of the third round of screening in those aged 50 years or more at entry and after the fourth screening round in those under 50 at entry. Breast cancers were treated according to stage at diagnosis and independently of mode of detection. In this report, age refers to age at entry to the study, unless specifically stated otherwise.
Results
The breast cancer rates in the study and control from randomisation to December 31, 1985 are shown in Table I . Figure I demonstrates the evolution of the cumulative rates of advanced cancer in the study and control groups during the progress of the study, for women aged 40-74 at entry. The significance of the difference appears in Table II. Table  III gives the mortality from breast cancer in the study and control groups. The cumulative mortality rates in the two groups by year since entry into the study are displayed in Figure 2 .
To examine the effect of screening on breast cancer mortality in greater detail we considered the screening status of women in the study group who died from breast cancer (Table IV) Ltd., 1987 Br. J. Cancer (1987 , 55, [547] [548] [549] [550] [551] (X% = 4.8, testing for trend) even though the interval was shorter in younger women. In each age group roughly onethird of the breast cancer deaths were observed in the group diagnosed at screening.
To investigate the ability of mammography to detect early cancers among women of different ages, the incidence of Stage II or worse, a figure close to the percentage of 610% in the control group, as calculated from Table I . Table VI shows the proportion of advanced cancers in each ten year age group among interval cases and those diagnosed at repeat screening, and for comparison, the controls. It should be noted that the interval cancer rates may be underestimated, as the knowledge that a repeat screening appointment is imminent may be disincentive to self- Particular emphasis is given in this report to the former. Both in this study and in the HIP study the survival of interval cancers has been similar to the survival of cancers in the control group. The reduction of breast cancer mortality should therefore be greater, the lower the proportion of the interval cancers. The results of this study provide a quantitative criterion for comparing different screening frequencies, Although this criterion is not explicitly in terms of reduced breast cancer mortality, it is in terms of a measure directly related to it. This measure, the proportional incidence of interval cancers, should give an early assessment of the effectiveness of the screening programme, which depends on both the frequency of screening and the sensitivity of the screening test. The proportion of cancers that appear as interval cancers with different screening intervals is shown in Table V and Figure 3 . Among women under age 50 the rate of interval cancers returns to the rate in the control group markedly more rapidly than in older women; in these younger women much of the effect of single-view mammography screening has disappeared in the second year after the screening examination. In the 50-69 age group, the incidence of interval cancers in the third year after screening is nearly half that in the control group of the same age. The information about the prognosis of cases diagnosed at repeat screening is not yet complete from this study. There are good indications, however, that the breast cancer mortality in this group will be closely related to the proportion of advanced carcinomas (see Table VI ). In these particular cases, screening has not been successful in preventing tumour growth to a potentially fatal stage. The primary reason is not poor sensitivity in the age groups 50-69; the low interval cancer rates during the first two years reflect the high sensitivity of mammography screening in this age group. Stage II and more advanced breast carcinomas accounted for 38% of the cancers detected at repeat screening in age group 40-49; 25% in age group 50-59 and 17% in age group 60-69. Adding these cases to the interval cancer cases, raises the number of carcinomas unaffected by screening to an unacceptably high level during the second year after screening in the age group 40-49 and during the third year after screening in the 50-69 year age group.
Analysis of the screening history of women dying from breast cancer reveals an age-related phenomenon (Table   VII) . Among women over 70, compliance was low and the effectiveness of the screening programme was correspondingly reduced, more than half of the deaths from breast cancer were observed in those who refused screening. Also, in the 60-69 age group, 34% of the breast cancer deaths occurred among the refusers. Thus, among women 50 and over, low compliance is a major factor impairing the effectiveness of mammography screening. If repeat screening is delayed in more than two years, the increasing rate of both interval cancers and of advanced cancers detected at repeat screening is an additional factor jeopardising the screening effect. By comparison, the sensitivity of screening women 40-49 with single-view mammography every two years is low, because this screening test permits the reappearance of too many interval cancers. These cancers contributed more than half of the total breast cancer deaths in this age group. The sensitivity of the screening examination should be increased; this can be done by using two-view mammography (Andersson et al., 1981; Bunnell et al., 1986) . In addition to the low sensitivity, the long interval time (2 years) allowed the occurrence of too many advanced cancers at repeat screening.
It is clear from these results that for women aged 40 to 49 years single-view mammography every two years is not a sufficiently effective screening policy. What is needed is a more sensitive test, more frequently applied; annual two-view mammography would probaIply provide substantial improvement. For women over the age of 50, there would seem to be little scope for much improvement by screening more frequently than every two years. Less frequent screening will lead to an appreciable increase in the frequency of interval cancers and also in the frequency of Stage II or more advanced tumours. It is tempting to consider randomised trials of the relative effectiveness of different screening intervals for women over 50. The logistics of such trials needs careful evaluation, however. In the Swedish trial, the results to date on mortality reflect mainly the effect of the initial round of screening. No effect was seen for three to four years and significance emerged after some seven years. To evaluate the effect of screening rounds after the first will clearly take considerably longer. The expected difference in breast cancer between, say, yearly 
